WCG Acquires Trifecta
WCG announced its acquisition of Trifecta Clinical, including its site communication platform InvestigatorSpace, virtual training programs, and safety documentation services.
Dave Young, Trifecta’s Founder and CEO, said, “We’re thrilled to be joining WCG, a company that shares our passion for improving the clinical trial process by delivering impactful solutions to age-old problems. This acquisition was a natural evolution for Trifecta.”
Moving forward, Trifecta will be known as WCG Trifecta, and will retain its leadership structure, along with its headquarters in Los Angeles, and locations in Indianapolis, Philadelphia, and Osaka, Japan.
For the full release, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
